Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to ...
In a report released yesterday, Jeffrey Hung from Morgan Stanley maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback